Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
Recruiting now NCT05023265
Run by Sunnybrook Health Sciences Centre · for 18 and older · All sexes
What this study is about
This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).
Who can join (things the study team will check)
✅ You may be able to join if…
- Patients ≥18 years old
- Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)
- Primary lesion >3 cm, or recurrent lesion following local ablative therapy
- Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting
- ECOG 0-2
- Written informed consent
- Participants must be able to understand the English-language or with the aid of a translator
🚫 You may not be able to join if…
- Primary Lesion >20cm
- Evidence of distant metastatic disease
- Previous abdominal RT in vicinity of kidney preventing definitive SBRT
- History of major radiosensitivity syndrome
- Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)
- Currently pregnant or lactating
Where this trial is running
- Sunnybrook Health Sciences, Toronto, Ontario, Canada
Who to contact
Chris Zehr · 416-480-6100 · chris.zehr@sunnybrook.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05023265.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.